Joint pain is a common clinical problem for which both inflammatory and degenerative joint diseases are major causes. The purpose of this study was to investigate the role of CB1 and CB2 cannabinoid receptors in the behavioral, histological, and neurochemical alterations associated with joint pain. The murine model of monosodium iodoacetate (MIA) was used to induce joint pain in knockout mice for CB1 (CB1KO) and CB2 cannabinoid receptors (CB2KO) and transgenic mice overexpressing CB2 receptors (CB2xP). In addition, we evaluated the changes induced by MIA in gene expression of CB1 and CB2 cannabinoid receptors and l-, d-and j-opioid receptors in the lumbar spinal cord of these mice. Wild-type mice, as well as CB1KO, CB2KO, and CB2xP mice, developed mechanical allodynia in the ipsilateral paw after MIA intra-articular injection. CB1KO and CB2KO demonstrated similar levels of mechanical allodynia of that observed in wild-type mice in the ipsilateral paw, whereas allodynia was significantly attenuated in CB2xP. Interestingly, CB2KO displayed a contralateral mirror image of pain developing mechanical allodynia also in the contralateral paw. All mouse lines developed similar histological changes after MIA intra-articular injection. Nevertheless, MIA intra-articular injection produced specific changes in the expression of cannabinoid and opioid receptor genes in lumbar spinal cord sections that were further modulated by the genetic alteration of the cannabinoid receptor system. These results revealed that CB2 receptor plays a predominant role in the control of joint pain manifestations and is involved in the adaptive changes induced in the opioid system under this pain state. Ó
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Introduction
Pain in joints is a major clinical problem mainly associated in older people with osteoarthritis, the most common form of arthritis [67] , whereas in young people it is mainly caused by inflammatory joint diseases such as rheumatoid arthritis. Currently, the therapeutic approaches to treat joint diseases are limited because no drugs are available to control the disease progression, and treatment with analgesic compounds has limited efficacy and significant side effects.
Several findings support interest in the endocannabinoid system as a new possible target for the development of innovative therapeutic approaches for joint pain associated with arthritis. The cannabinoid system has been involved in a wide range of pathophysiological processes [32] and plays an important role in pain modulation [15] . At least 2 different cannabinoid receptors, CB1R and CB2R, have been identified [36, 40] . CB1R is extensively expressed in the central nervous system and peripheral sensory neurons, while CB2R has been mainly found in peripheral tissues and is also expressed in neurons [63] . The analgesic effects of CB1R agonists are well established (reviewed in [10]), and the selective agonism of CB2R may constitute a new strategy for treating chronic pain (reviewed in [19, 66] ). Behavioral and electrophysiological studies have demonstrated the antinociceptive effects of CB1 and CB2 agonists in different models of chronic pain and arthritis [11, 54, 56, 58, 65, 68] . In addition, in vitro studies identified the expression of CB1R and CB2R on chondrocytes [38] and revealed the potential ability of cannabinoids to prevent cartilage degradation [37] . Interestingly, the functional expression of CB1R and CB2R in synovia was detected in patients with osteoarthritis, together with increased levels of the endocannabinoids anandamide (AEA) and 2-arachidonyl glycerol (2-AG) in the synovial fluid [52] . Enhanced levels of AEA and 2-AG were also demonstrated in the
